GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Exelixis, Inc. (EXEL) [hlAlert]

Rating:
Buy EXEL
up 13.19 %

Exelixis, Inc. (EXEL) rated Buy with price target $9 by Stifel Nicolaus

Posted on: Friday,  Nov 30, 2012  8:25 AM ET by Stifel Nicolaus

Stifel Nicolaus rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 11/30/2012. Previously Stifel Nicolaus rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 03/15/2012.,
when the stock price was $5.38. Since then, Exelixis, Inc. has gained 13.20% as of 08/27/2015's recent price of $6.09.
If you would have followed the previous Stifel Nicolaus's recommendation on EXEL, you would have gained 13.19% of your investment in 1260 days.

Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. Its most advanced pharmaceutical programs focus on drug discovery and development of small molecule drugs for cancer. The Company has nine compounds in clinical development: XL184, XL147, XL765, XL518, XL228, XL019, XL139, XL413 and XL888. Exelixis also has out-licensed to third parties for further development and commercialization of five compounds in preclinical and clinical development: XL880, XL281, XL652, XL550 and FXR Program. The Company has established commercial collaborations with several pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. and GlaxoSmithKline.

Stifel Nicolaus research focuses on all market caps, but is a leader in small- and mid-cap research. The department is staffed predominately with industry professionals from outside Wall Street. In fact, approximately 50% of its analysts have hands-on work experience in the industry that they research. Stifel Nicolaus believes industry experience, its opportunistic approach, and broad market cap coverage drive excess returns and its award-winning franchise.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/30/2012 8:25 AM Buy
None
4.94 9.00
as of 12/31/2012
1 Week down  -0.21 %
1 Month down  -6.35 %
3 Months down  -5.18 %
1 YTD down  -7.48 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/15/2012 8:25 AM Buy
None
5.38 8.00
8/17/2011 8:25 AM Hold
None
6.93 8.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy